drugset / Trial / NCT05165771
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study is to evaluate the effect of GS-5718 versus placebo for the treatment of rheumatoid arthritis (RA) as measured by change from baseline in Disease Activity Score (DAS) based on 28 joints using C-reactive protein (CRP) (DAS28\[CRP\]) at Week 12.
Timeline
- Start
- 2022-07
- Primary completion
- 2023-02
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edecesertib | Small molecule | — | Oral |
| Subject | Tofacitinib | Small molecule | 5 mg | Oral |